9PT Stock Chart & Stats
€0.93
<€0.01(0.86%)
At close: 4:00 PM EDT
€0.93
<€0.01(0.86%)
Day’s Range― - ―
52-Week Range€0.86 - €1.63
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€61.32M
Enterprise Value-€58.77
Total Cash (Recent Filing)€158.10M
Total Debt (Recent Filing)€28.74M
Price to Earnings (P/E)―
Beta0.28
Next Earnings
Nov 05, 2026EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.49
Shares Outstanding61,921,898
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.41
Price to Sales (P/S)0.00
P/FCF Ratio-0.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€2.16Price Target Upside132.20% Upside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)-1.23
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
FDA Fast Track DesignationFDA Fast Track can support more frequent regulatory interaction and potentially streamline development of PLN-101095 in a defined oncology setting. It strengthens the program’s regulatory positioning, although Phase 1a/1b data are not expected until 2027.
Clinical Pipeline And Platform ProgressStrong FORTIFY enrollment improves the prospect of generating clinical evidence for PLN-101095, while the proprietary integrin-targeted delivery platform could support multiple future programs. These assets provide strategic optionality beyond one indication.
Modest Balance-sheet LeverageDebt of about $28.7M versus $146.9M of equity implies modest leverage at roughly 0.20 debt-to-equity. This relatively lighter debt burden gives Pliant more balance-sheet flexibility to fund development than a highly leveraged peer.
Bears Say
No Established Revenue BaseRecent periods show effectively no revenue and a TTM net loss of about $92.3M, following a $149.3M loss in 2025. Without marketed products or recurring sales, operating performance depends on pipeline progress and external financing rather than established commercial cash generation.
Persistent Cash BurnTTM operating and free cash flow are both about negative $70.9M. Although burn improved from roughly negative $128.7M in 2025 and negative $159.4M in 2024, ongoing outflows mean continued funding is needed to sustain clinical development.
Equity Erosion And Dilution RiskEquity fell from about $473.6M in 2023 to $181.2M in 2025 and $146.9M TTM, reflecting cumulative losses and cash consumption. If this trajectory persists, future capital raises could dilute existing holders and constrain strategic flexibility.
Pliant Therapeutics News
9PT FAQ
What was Pliant Therapeutics’s price range in the past 12 months?
Pliant Therapeutics lowest stock price was €0.86 and its highest was €1.63 in the past 12 months.
What is Pliant Therapeutics’s market cap?
Pliant Therapeutics’s market cap is €61.32M.
When is Pliant Therapeutics’s upcoming earnings report date?
Pliant Therapeutics’s upcoming earnings report date is Nov 05, 2026 which is in 72 days.
How were Pliant Therapeutics’s earnings last quarter?
Pliant Therapeutics released its earnings results on Aug 11, 2026. The company reported -€0.311 earnings per share for the quarter, missing the consensus estimate of -€0.295 by -€0.016.
Is Pliant Therapeutics overvalued?
According to Wall Street analysts Pliant Therapeutics’s price is currently Undervalued.
Does Pliant Therapeutics pay dividends?
Pliant Therapeutics does not currently pay dividends.
What is Pliant Therapeutics’s EPS estimate?
Pliant Therapeutics’s EPS estimate is -0.33.
How many shares outstanding does Pliant Therapeutics have?
Pliant Therapeutics has 61,921,898 shares outstanding.
What happened to Pliant Therapeutics’s price movement after its last earnings report?
Pliant Therapeutics reported an EPS of -€0.311 in its last earnings report, missing expectations of -€0.295. Following the earnings report the stock price went down -2.876%.
Which hedge fund is a major shareholder of Pliant Therapeutics?
Currently, no hedge funds are holding shares in DE:9PT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pliant Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-87.90%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-36.67%
Trailing 12-Months
Company Description
Pliant Therapeutics
Pliant Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to discovering, advancing, and bringing to market innovative therapies for fibrotic and related diseases across the United States. Its flagship investigational product, PLN-74809, is an orally administered, small-molecule, dual-selective inhibitor targeting both avß6 and avß1 integrins, which is currently progressing through three distinct Phase 2a clinical trials. The company's pipeline also includes PLN-1474, a small-molecule selective inhibitor of avß1, which has successfully completed its Phase 1 clinical assessment for treating liver fibrosis associated with nonalcoholic steatohepatitis (NASH). Furthermore, Pliant is nurturing two additional integrin-based initiatives in preclinical development: one focused on oncology, and another involving an allosteric agonistic monoclonal antibody designed to act upon an undisclosed integrin receptor for the treatment of various muscular dystrophies, including Duchenne muscular dystrophy. Founded in 2015, Pliant Therapeutics, Inc. maintains its corporate headquarters in South San Francisco, California.
9PT Stock 12 Month Forecast
Average Price Target
€2.16
▲(132.20% Upside)